Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas

Despite substantially improved survival with rituximab-based treatment regimens, there is an unmet medical need for better treatments of B-cell lymphoma, particularly for patients with relapsed or refractory disease. Retreatment with rituximab exerts a limited effect in these patients, and platinum-...

Descripción completa

Detalles Bibliográficos
Autor principal: Yi, Jun Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093997/
https://www.ncbi.nlm.nih.gov/pubmed/33935029
http://dx.doi.org/10.5045/br.2021.2020320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093997/
https://www.ncbi.nlm.nih.gov/pubmed/33935029
http://dx.doi.org/10.5045/br.2021.2020320

Ejemplares similares